FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction.
Correction to: Oncogene (2015) 34, 2505–2515; doi:10.1038/onc. 2014.184; published online 7 July 2014. Since the publication of the above paper, the authors found a misplacing band in Figure 2e. The correct version of the figure is given below. The correction does not affect the validity of the data presented and does not limit the conclusions drawn in the paper. The authors apologize for this mistake.